Tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine
C67H82ClF4N15O4 — CID 160525227
Data last refreshed: (MolForge compound catalog, from PubChem)
About Tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine
Tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine (PubChem CID 160525227) has the molecular formula C67H82ClF4N15O4 and a molecular weight of 1272.94 g/mol. Its IUPAC name is tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine.
Molecular Properties
| Compound Name | Tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine |
|---|---|
| PubChem CID | 160525227 |
| Molecular Formula | C67H82ClF4N15O4 |
| Molecular Weight | 1272.94 g/mol |
| Exact Mass | 1271.63 |
| IUPAC Name | tert-butyl (1S,6R)-7-[(2-chloropyrimidin-5-yl)methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;tert-butyl (1S,6R)-7-[[2-[[5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)-2-pyridinyl]methyl]pyrimidin-5-yl]methyl]-1-methyl-3,7-diazabicyclo[4.2.0]octane-3-carboxylate;5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyridin-2-amine |
| SMILES | CC(C)(C)OC(=O)N1CC[C@H]2N(Cc3cnc(Cl)nc3)C[C@@]2(C)C1.Cc1nc2c(F)cc(-c3cc(Cc4ncc(CN5C[C@@]6(C)CN(C(=O)OC(C)(C)C)CC[C@@H]56)cn4)ncc3F)cc2n1C(C)C.Cc1nc2c(F)cc(-c3cc(N)ncc3F)cc2n1C(C)C |
| InChI | InChI=1S/C34H41F2N7O2.C17H25ClN4O2.C16H16F2N4/c1-20(2)43-21(3)40-31-26(35)10-23(11-28(31)43)25-12-24(37-16-27(25)36)13-30-38-14-22(15-39-30)17-42-19-34(7)18-41(9-8-29(34)42)32(44)45-33(4,5)6;1-16(2,3)24-15(23)21-6-5-13-17(4,10-21)11-22(13)9-12-7-19-14(18)20-8-12;1-8(2)22-9(3)21-16-12(17)4-10(5-14(16)22)11-6-15(19)20-7-13(11)18/h10-12,14-16,20,29H,8-9,13,17-19H2,1-7H3;7-8,13H,5-6,9-11H2,1-4H3;4-8H,1-3H3,(H2,19,20)/t29-,34-;13-,17-;/m11./s1 |
| InChIKey | QUUKVVWUOMCEJD-HLLDWZEXSA-N |
| XLogP | 13.29 |
| TPSA | 204.56 Ų |
| H-Bond Donors | 1 |
| H-Bond Acceptors | 17 |
| Rotatable Bonds | 10 |
| Heavy Atoms | 91 |
| Complexity | — |
Lipinski Rule of Five
3 violations
| Rule | Value |
|---|---|
| MW ≤ 500 | 1272.94 |
| LogP ≤ 5 | 13.29 |
| H-Bond Donors ≤ 5 | 1 |
| H-Bond Acceptors ≤ 10 | 17 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 160525227 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.